Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative.
Aging
Alzheimer’s disease
Biomarkers
Dementia
Frailty
Journal
GeroScience
ISSN: 2509-2723
Titre abrégé: Geroscience
Pays: Switzerland
ID NLM: 101686284
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
06
08
2020
accepted:
23
10
2020
pubmed:
20
11
2020
medline:
1
6
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
The present study aimed at investigating if the main biomarkers of Alzheimer's disease (AD) neuropathology and their association with cognitive disturbances and dementia are modified by the individual's frailty status. We performed a cross-sectional analysis of data from participants with normal cognition, mild cognitive impairment (MCI), and AD dementia enrolled in the Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2) study. Frailty was operationalized by computing a 40-item Frailty Index (FI). The following AD biomarkers were considered and analyzed according to the participants' frailty status: CSF Aβ
Identifiants
pubmed: 33210215
doi: 10.1007/s11357-020-00293-y
pii: 10.1007/s11357-020-00293-y
pmc: PMC8110661
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1039-1051Subventions
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Références
Espay AJ, Vizcarra JA, Marsili L, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019;92(7):329–37. https://doi.org/10.1212/WNL.0000000000006926 .
doi: 10.1212/WNL.0000000000006926
pubmed: 30745444
pmcid: 6382364
Illán-Gala I, Pegueroles J, Montal V, et al. Challenges associated with biomarker-based classification systems for Alzheimer’s disease. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:346–57. https://doi.org/10.1016/j.dadm.2018.03.004 .
doi: 10.1016/j.dadm.2018.03.004
Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–62. https://doi.org/10.1016/S0140-6736(12)62167-9 .
doi: 10.1016/S0140-6736(12)62167-9
pubmed: 23395245
Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14(6):392–7. https://doi.org/10.1016/j.jamda.2013.03.022 .
doi: 10.1016/j.jamda.2013.03.022
pubmed: 23764209
pmcid: 4084863
Hoogendijk EO, Afilalo J, Ensrud KE, et al. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365–75. https://doi.org/10.1016/S0140-6736(19)31786-6 .
doi: 10.1016/S0140-6736(19)31786-6
pubmed: 31609228
Rockwood K, Howlett SE. Age-related deficit accumulation and the diseases of ageing. Mech Ageing Dev. 2019;180:107–16. https://doi.org/10.1016/j.mad.2019.04.005 .
doi: 10.1016/j.mad.2019.04.005
pubmed: 31002924
Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001;1:323–36. https://doi.org/10.1100/tsw.2001.58 .
doi: 10.1100/tsw.2001.58
pubmed: 12806071
pmcid: 6084020
Rogers NT, Steptoe A, Cadar D. Frailty is an independent predictor of incident dementia: evidence from the English Longitudinal Study of Ageing. Sci Rep. 2017;7. https://doi.org/10.1038/s41598-017-16104-y .
Song X, Mitnitski A, Rockwood K. Nontraditional risk factors combine to predict Alzheimer disease and dementia. Neurology. 2011;77(3):227–34. https://doi.org/10.1212/WNL.0b013e318225c6bc .
doi: 10.1212/WNL.0b013e318225c6bc
pubmed: 21753161
pmcid: 3136058
Kelaiditi E, Andrieu S, Cantet C, et al. Frailty Index and incident mortality, hospitalization, and institutionalization in Alzheimer’s disease: data from the ICTUS study. J Gerontol A Biol Sci Med Sci. 2015;71(4):543–8. https://doi.org/10.1093/gerona/glv137 .
doi: 10.1093/gerona/glv137
pubmed: 26273022
Kelaiditi E, Canevelli M, Andrieu S, et al. Frailty Index and cognitive decline in Alzheimer’s disease: data from the Impact of Cholinergic Treatment USe study. J Am Geriatr Soc. 2016;64(6):1165–70. https://doi.org/10.1111/jgs.13956 .
doi: 10.1111/jgs.13956
pubmed: 27321595
Trebbastoni A, Canevelli M, D’Antonio F, et al. The impact of frailty on the risk of conversion from mild cognitive impairment to Alzheimer’s disease: evidences from a 5-year observational study. Front Med. 2017;4. https://doi.org/10.3389/fmed.2017.00178 .
Canevelli M, Trebbastoni A, Quarata F, et al. External validity of randomized controlled trials on Alzheimer’s disease: the biases of frailty and biological aging. Front Neurol. 2017;8:628. https://doi.org/10.3389/fneur.2017.00628 .
doi: 10.3389/fneur.2017.00628
pubmed: 29230192
pmcid: 5712065
Maltais M, De Souto Barreto P, Hooper C, et al. Association between brain β-amyloid and frailty in older adults. J Gerontol Ser A. 2019;74(11):1747–52. https://doi.org/10.1093/gerona/glz009 .
doi: 10.1093/gerona/glz009
Wallace LMK, Theou O, Godin J, et al. Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer’s disease: a cross-sectional analysis of data from the Rush Memory and Aging Project. Lancet Neurol. 2019;18(2):177–84. https://doi.org/10.1016/S1474-4422(18)30371-5 .
doi: 10.1016/S1474-4422(18)30371-5
pubmed: 30663607
Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–62. https://doi.org/10.1016/j.jalz.2011.03.004 .
doi: 10.1016/j.jalz.2011.03.004
pubmed: 21514247
pmcid: 3096735
Blennow K. Biomarkers in Alzheimer’s disease drug development. Nat Med. 2010;16(11):1218–22. https://doi.org/10.1038/nm.2221 .
doi: 10.1038/nm.2221
pubmed: 21052077
Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018 .
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
pmcid: 5958625
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84. https://doi.org/10.1016/S1474-4422(16)00070-3 .
doi: 10.1016/S1474-4422(16)00070-3
pubmed: 27068280
Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–8.
doi: 10.1001/archneur.56.3.303
pubmed: 10190820
Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201–9. https://doi.org/10.1212/WNL.0b013e3181cb3e25 .
doi: 10.1212/WNL.0b013e3181cb3e25
pubmed: 20042704
pmcid: 2809036
Wechsler DA. Wechsler Memory Scale–Revised. New York Psychological Corporation 1987.
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.
doi: 10.1212/WNL.34.7.939
pubmed: 6610841
Jack CR, Barnes J, Bernstein MA, et al. Magnetic resonance imaging in ADNI. Alzheimers Dement. 2015;11(7):740–56. https://doi.org/10.1016/j.jalz.2015.05.002 .
doi: 10.1016/j.jalz.2015.05.002
pubmed: 26194310
pmcid: 4523217
Jagust WJ, Landau SM, Koeppe RA, et al. The Alzheimer’s Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement. 2015;11(7):757–71. https://doi.org/10.1016/j.jalz.2015.05.001 .
doi: 10.1016/j.jalz.2015.05.001
pubmed: 26194311
pmcid: 4510459
Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56(4):567–74. https://doi.org/10.2967/jnumed.114.148981 .
doi: 10.2967/jnumed.114.148981
pubmed: 25745095
Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403–13. https://doi.org/10.1002/ana.21610 .
doi: 10.1002/ana.21610
pubmed: 19296504
pmcid: 2696350
Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a Frailty Index. BMC Geriatr. 2008;8:24. https://doi.org/10.1186/1471-2318-8-24 .
doi: 10.1186/1471-2318-8-24
pubmed: 18826625
pmcid: 2573877
Hwang SJ, Beaty TH, Liang KY, et al. Minimum sample size estimation to detect gene-environment interaction in case-control designs. Am J Epidemiol. 1994;140(11):1029–37. https://doi.org/10.1093/oxfordjournals.aje.a117193 .
doi: 10.1093/oxfordjournals.aje.a117193
pubmed: 7985651
Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470–81. https://doi.org/10.1016/j.jalz.2018.01.010 .
doi: 10.1016/j.jalz.2018.01.010
pubmed: 29499171
pmcid: 6119541
Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578–86. https://doi.org/10.1002/ana.23650 .
doi: 10.1002/ana.23650
pubmed: 23109153
pmcid: 3786871
Ou Y-N, Xu W, Li J-Q, et al. FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study. Alzheimers Res Ther. 2019;11(1):57. https://doi.org/10.1186/s13195-019-0512-1 .
doi: 10.1186/s13195-019-0512-1
pubmed: 31253185
pmcid: 6599313
Wallace L, Theou O, Rockwood K, Andrew MK. Relationship between frailty and Alzheimer’s disease biomarkers: a scoping review. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:394–401. https://doi.org/10.1016/j.dadm.2018.05.002 .
doi: 10.1016/j.dadm.2018.05.002
Bisset ES, Howlett SE. The biology of frailty in humans and animals: understanding frailty and promoting translation. Aging Med. 2019;2(1):27–34. https://doi.org/10.1002/agm2.12058 .
doi: 10.1002/agm2.12058
Canevelli M, Cesari M, Raganato R, et al. Role of frailty in the assessment of cognitive functioning. Mech Ageing Dev. 2019;181:42–6. https://doi.org/10.1016/j.mad.2019.111122 .
doi: 10.1016/j.mad.2019.111122
pubmed: 31170404
Weiner MW, Aisen PS, Jack CR, et al. The Alzheimer’s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):202–11. e7. https://doi.org/10.1016/j.jalz.2010.03.007 .
doi: 10.1016/j.jalz.2010.03.007
pubmed: 20451868
pmcid: 2927112
Boyle PA, Yu L, Wilson RS, Leurgans SE, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74–83. https://doi.org/10.1002/ana.25123 .
doi: 10.1002/ana.25123
pubmed: 29244218
pmcid: 5876116